...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Combo with Enzalutamide in Phase 2 Metastatic Prostate Cancer Clinical Trial and with Pfizer’s PARPi, talazoparib, in Phase 1b/2 Triple Negative Breast Cancer Trial

Free
Message: Rumors starting again

Posted question for AGM Does management have a clear plan for company and if nor and we continue as an academic exercise will they give shareholders liquidity through a Public listing.

Share
New Message
Please login to post a reply